Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous platelet-rich plasma (PRP) is a therapeutic concentrate of platelets and associated growth factors derived from a patient's own peripheral blood. The preparation process involves centrifuging whole blood to separate and concentrate the platelet fraction, which is rich in alpha-granules. Upon activation, these granules release a variety of bioactive proteins, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF). These factors are thought to promote tissue repair, angiogenesis, and the modulation of inflammatory responses. In the context of Autism Spectrum Disorder (ASD), PRP is being investigated for its potential neuroprotective and anti-inflammatory effects. At the Iffat Anwar Medical Complex, it is being evaluated as part of a multi-modal regenerative therapy that also includes photo-biomodulation and umbilical cord-derived exosomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous platelet-rich plasma (Iffat Anwar Medical Complex).